The purpose of this study is to develop population pharmacokinetic models for antiepileptic drugs in a pediatric population. The interest of these models is multiple: * describe the pharmacokinetics of these molecules in children and explain the inter-individual variability of concentrations through covariates such as weight, age, co-treatments, genetic polymorphisms and renal function; * estimate maximum, minimum and exposure concentrations from the individual pharmacokinetic parameters for each patient; * propose adaptations of doses for certain classes of children (according to age, weight etc.) and individualize the doses.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Volume of distribution
Timeframe: through study completion, an average of 5 years
Absorption constant
Timeframe: through study completion, an average of 5 years
Clearance
Timeframe: through study completion, an average of 5 years